Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function

Blood Pressure

Volumn 19, Issue 6, 2010, Pages 359-365

  Shiga, Tsuyoshi ^a   Kasanuki, Hiroshi ^a   Hagiwara, Nobuhisa ^a   Sumiyoshi, Tetsuya ^b   Honda, Takashi ^c   Haze, Kazuo ^d   Takagi, Atsushi ^a   Kawana, Masatoshi ^a   Origasa, Hideki ^e   Ogawa, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b SAKAKIBARA HEART INSTITUTE   (Japan)

^c Saisei kai Kumamoto Hospital   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Angiotensin receptor blocker; Coronary artery disease; Hypertension; Renal function

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT RECEPTOR; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RISK FACTORS; TETRAZOLES;

EID: 78649271384     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051003802475     Document Type: Article

References (33)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med. 2004;351:1296-1305.
2. Beddhu S, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int. 2002;62:1776-1783.
3. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: The Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Nephrol. 2007;18:1307-1315.
4. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet. 2005;366:2026-2033.
5. Raij L. The pathophysiologic basis for blocking the renninangiotensin system in hypertensive patients with renal disease. Am J Hypertens. 2005;18:95S-99S.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
7. Barrios V, Escobar C, Murga N, de Pablo C, Bertomeu V, Calderó;n A, et al. Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice. J Hypertens. 2008;26:2230-2235.
8. Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, et al, for the HIJ-CREATE Investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J. 2009;30:1203-1212.
9. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992;1:113-119
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
11. Hosoda S, Kimata S, Tamura K, Nakamura M, Toshima H, Shibata J, et al. Follow-up of 2, 733 Japanese patients with myocardial infarction. Jpn Circ J. 1995;59:121-129.
12. Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, et al, on behalf of the Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Am J Cardiol. 1999;83:1308-1313.
13. Braunwald E. Unstable angina. A classification. Circulation. 1989;80:410-414.
14. Gupta R, Bimbaum Y, Uretsky BF. The renal patient with coronary artery disease. Current concepts and dilemmas. J Am Coll Cardiol. 2004;44:1343-53.
15. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol. 2009;53:2129-2140.
16. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-1295.
17. Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) study. Circulation. 2004;110:3667-3673.
18. Yamaguchi J, Kasanuki H, Ishii Y, Yagi M, Ogawa H, Fujii S, et al, for the HIJC Study Group. Prognostic significance of serum creatinine concentration for in-hospital mortality in patients with acute myocardial infarction who underwent successful primary percutaneous coronary intervention (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] registry. Am J Cardiol. 2004;93:1526-1528.
19. Ruilope LM. Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr Med Res Opin. 2008;24:1285-1293.
20. The PEACE Trial Investigators. Angiotensin-convertingenzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-2068.
21. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
22. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
23. Solomon SD, Rice MM, Jablonski KA, Jose P, Domanski M, Sabatine M, et al, for the Prevention of Events with ACE inhibition (PEACE) Investigators. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) Trial. Circulation. 2006;114:26-31.
24. Schmieder RE, Hilgers K, Schlaich MP, Schmidt BMW. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208-1219.
25. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
26. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al, for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
27. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques. Potential implications for inflammation and plaque instability. Circulation. 2000;101:1372-1378.
28. Neri Serneri GG, Boddi M, Modesti PA, Coppo M, Cecioni I, Toscano T, et al. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res. 2004;94:1630-1637.
29. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD (P) H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res. 2000;87:1195-1201.
30. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Böhm M, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 2004;94:534-541.
31. Schieffer B, Bünte C, Witte J, Hoeper K, Böger RH, Schwedhelm E, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004;44:362-368.
32. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al, for the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension. 2008;51:393-398.
33. Ohishi M, Takagi T, Ito N, Tatara Y, Hayashi N, Shiota A, et al. Renal protective effect in hypertensive patients: The high doses of angiotensin II receptor blocker (HARB) study. Hypertens Res. 2007;30:1187-1192.